Study: Healthcare Marketers Report Their Biggest Success in 2022 Was Driving Patient Appointments

New report from Actium Health reveals 3 out of 10 marketers typically exceed their organization’s appointment-booking goals PALO ALTO, Calif.–(BUSINESS WIRE)–Actium Health, healthcare’s leading CRM Intelligence company, today released the results of a study of healthcare marketers that reveals their priorities, budgets, successes and failures – and how best to activate patients to take action … [Read more…]

Modivcare to Report First Quarter 2023 Financial Results

DENVER–(BUSINESS WIRE)–Modivcare Inc. (“Modivcare” or the “Company”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced that the Company is scheduled to report financial results for the first quarter ended March 31, 2023, on Thursday, May 4, 2023, before the market … [Read more…]

Genefic’s Watson Rx Solutions Earns Prestigious NABP Merchant Accreditation

Healthcare subsidiary receives pharmaceutical industry honor; will have “.pharmacy” website created SAN DIEGO–(BUSINESS WIRE)–#dalradasubsidiary—Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada”), a problem-solving innovator that takes on complex, multi-disciplinary challenges in healthcare, clean energy, precision manufacturing, and technology, announced today that Watson Rx Solutions (Watson Rx), the pharmacy operating under its healthcare division, Genefic, has received Healthcare … [Read more…]

Affini-T Therapeutics Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs

Multi-year research collaboration with Memorial Sloan Kettering Cancer Center (MSK) aims to propel future innovation for patients with solid tumors MSK’s Christopher A. Klebanoff, M.D., to serve Affini-T as Scientific Co-founder and Advisor BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced … [Read more…]

Akili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ET

BOSTON–(BUSINESS WIRE)–$AKLI #ADHD–Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the first quarter of 2023 on Thursday, May 11, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com … [Read more…]

Ventus Therapeutics to Present at 2023 Bloom Burton & Co. Healthcare Investor Conference

WALTHAM, Mass. & MONTREAL–(BUSINESS WIRE)–Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2023 Bloom Burton & Co. … [Read more…]

Twist Bioscience Launches TCR and CAR Libraries to Enable the Development of Cell Therapies

TCR and CAR libraries enable comprehensive screening of combinations of custom gene parts including domains from TCRs and CARs Information about the offering available at AACR Annual Meeting 2023 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, … [Read more…]

Aviceda Announces FDA Clearance of the Investigational New Drug (IND) Application for AVD-104, a Novel Glyco-Mimetic Nanoparticle, Enabling Initiation of Phase 2 Clinical Trials for the Treatment of Geographic Atrophy from Macular Degeneration

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to modulate the innate immune system and alleviate chronic, non-resolving inflammation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for AVD-104, enabling the company to proceed with initiating … [Read more…]

Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis

Top-Line Results Expected in the First Half of 2023 LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced completion of enrollment in the Phase 3 INVIGORATE-2 clinical trial of topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of allergic conjunctivitis. “Today, millions of allergic conjunctivitis patients rely on therapies that … [Read more…]

Sixteen US Eye Physicians Named to Castle Connolly’s 2023 Top Doctors List

SARASOTA, Fla.–(BUSINESS WIRE)–#Eyecare–US Eye, a patient-centric network of premium eye care practices, is proud to announce that sixteen US Eye physicians have been named to the 2023 list of Top Doctors published by Castle Connolly Medical, Ltd. Castle Connolly Top Doctors are peer-nominated, and thoroughly vetted by a physician-led research team. The Castle Connolly research … [Read more…]